Overview

A Study to Evaluate the Effects of 4 Weeks Treatment With Subcutaneous Elamipretide on Left Ventricular Function in Subjects With Stable Heart Failure With Preserved Ejection Fraction

Status:
Completed

Trial end date:
2017-06-02

Target enrollment:

Participant gender:

Summary

This is a multi-center, randomized, double-blind, placebo-controlled study in subjects with stable heart failure with preserved ejection fraction (HFpEF) to evaluate the effects of 4 weeks treatment with subcutaneous MTP-131 (elampretide) on left ventricular function.

Phase:

Phase 2

Details

Lead Sponsor:

Stealth BioTherapeutics Inc.

Collaborators:

Charite University, Berlin, Germany
KKS Charite
SCIRENT Clinical Research and Science d.o.o.